Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Blood advances · 2022
    EKEllen K. RitchieGJGail J Roboz
    PMID: 35420672PMCID: PMC9631575DOIFirst author35 citations
  2. 2
    Leukemia & lymphoma · 2023
    EKEllen K. Ritchie
    PMID: 37019445DOIFirst author6 citations
  3. 3
    Leukemia & lymphoma · 2022
    EKEllen K. Ritchie
    PMID: 36205505DOIFirst author8 citations

Publications

107 publications

Funding

1 grant
Completed grants (1)
  • Co-I
    Stopping Tyrosine Kinase Inhibitors in CML Patients (STOP-TKIs)
    National Cancer Institute · 2014–2020 · via Medical College of Wisconsin
    No publications yet
    R01CA185798-02

Clinical research

22 studies
Completed & closed trials (22)
  • PI
    A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
    PHASE2 · Karyopharm Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2026)
    Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia
    NCT05980806
  • PI
    A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
    PHASE2 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2025)
    Myelofibrosis (MF)
    NCT03222609
  • PI
    A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
    PHASE1; PHASE2 · Incyte Corporation · IRB STUDY CLOSURE (as of 2025)
    Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
    NCT04455841
  • PI
    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
    PHASE1 · Incyte Corporation · CLOSED TO ACCRUAL (as of 2025)
    Myelofibrosis; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome; Myeloproliferative Neoplasm; Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis); ET (Essential Thrombocythemia)
    NCT04279847
  • PI
    Clinical and Pathologic Features of Relapsed/Refractory B-cell_x000D_ Acute Lymphoblastic Leukemia Responsive vs. Not Responsive to_x000D_ Inotuzumab Ozogamicin
    Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
    PHASE2 · Alliance for Clinical Trials in Oncology · IRB STUDY CLOSURE (as of 2025)
    B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
    NCT03739814
  • PI
    A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera
    PHASE2 · Protagonist Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2025)
    Polycythemia Vera
    NCT04057040
  • PI
    A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
    PHASE2 · Incyte, Inc. · IRB STUDY CLOSURE (as of 2025)
    MPN (Myeloproliferative Neoplasms)
    NCT03011372
  • PI
    Compassionate Use of Ziftomenib (KO-539) for Treatment of Acute Myeloid Leukemia in Patient C-D_x000D_
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
  • PI
    An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)
    PHASE3 · Protagonist Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2024)
    Polycythemia Vera
    NCT06033586
  • PI
    Compassionate Use of Tamibarotene for Treatment of Acute Promyelocytic Leukemia (APL) in Patient V-C-P
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
  • PI
    A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
    PHASE3 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2024)
    Myelofibrosis (MF)
    NCT04472598
  • PI
    A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
    PHASE1 · Forty Seven, Inc. · IRB STUDY CLOSURE (as of 2024)
    Hematological Malignancies
    NCT03248479
  • PI
    ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
    PHASE3 · Forty Seven, Inc. · IRB STUDY CLOSURE (as of 2023)
    Myelodysplastic Syndromes
    NCT04313881
  • PI
    A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
    PHASE2; PHASE3 · Kartos Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2023)
    Primary Myelofibrosis (PMF); Post-Polycythemia Vera MF (Post-PV-MF); Post-Essential Thrombocythemia MF (Post-ET-MF)
    NCT03662126
  • PI
    Compassionate Use of Tamibarotene for Treatment of Relapsed Acute Promyelocytic Leukemia in Patient V-C-P
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
  • PI
    A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
    PHASE1 · AbbVie Inc. · CLOSED TO ACCRUAL (as of 2023)
    Myelofibrosis (MF)
    NCT04454658
  • PI
    Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis
    PHASE2 · Actuate Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2023)
    Myelofibrosis
    NCT04218071
  • PI
    A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
    PHASE2 · IMAGO BioSciences, Inc. · IRB STUDY CLOSURE (as of 2022)
    Essential Thrombocythemia
    NCT04254978
  • PI
    A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
    PHASE1 · AbbVie Inc. · IRB STUDY CLOSURE (as of 2022)
    Acute Myeloid Leukemia (AML)
    NCT03625505
  • PI
    Phase I Trial, With an Expansion Cohort, of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Combination With Gemtuzumab in Subjects With Acute Myeloid Leukemia >55 Years of Age Who Have Not Been Treated With Intensive Chemotherapy
    PHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2022)
    Acute Myeloid Leukemia
    NCT03878927
  • PI
    Phase 1/2 Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    PHASE1; PHASE2 · Astellas Pharmaceuticals US, Inc. · IRB STUDY CLOSURE (as of 2021)
    Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
    NCT03730012

External relationships

Other

Incyte, Inc. · Jazz Pharmaceuticals, Inc. · Takeda Pharmaceutical Company Limited